Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Headache, Migraine

Conditions

Headache, Migraine

Trial Timeline

Sep 6, 2022 → Nov 1, 2024

NCT ID

NCT05503082

About Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]

Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy] is a approved stage product being developed by AbbVie for Headache, Migraine. The current trial status is active. This product is registered under clinical trial identifier NCT05503082. Target conditions include Headache, Migraine.

What happened to similar drugs?

8 of 20 similar drugs in Headache, Migraine were approved

Approved (8) Terminated (1) Active (11)

✅Galcanezumab-GnlmEli LillyApproved

✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved

✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved

✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved

✅Rimegepant + ZavegepantPfizerApproved

✅Acetylsalicylic acid (Aspirin, BAYE4465) + Acetylsalicylic acid (Aspirin, BAYE4465) + Ibuprofen + Ibuprofen + PlaceboBayerApproved

✅AbobotulinumtoxinA + Normal salineIpsenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05503082	Approved	Active	Sep 6, 2022	Nov 1, 2024	Headache, Migraine

Competing Products

20 competing products in Headache, Migraine

See all competitors

Product	Company	Stage	Hype Score
DFN-15 Active	Dr. Reddy's Laboratories	Phase 3	37
DFN-11 Injection	Dr. Reddy's Laboratories	Phase 2	24
Placebo + LY2300559	Eli Lilly	Phase 2	27
Ketorolac + Prochlorperazine + Diphenhydramine	Assertio Holdings	Phase 2	17
Aricept (donepezil hydrochloride)	Eisai	Phase 2	35
Galcanezumab 300 mg + Placebo	Eli Lilly	Phase 3	40
Galcanezumab	Eli Lilly	Phase 3	40
Galcanezumab-Gnlm	Eli Lilly	Approved	43
LY2590443 + Placebo injection + Sumatriptan + Placebo capsule	Eli Lilly	Phase 2	27
LY2951742 + Placebo	Eli Lilly	Phase 2	35
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 2	35
Soy Isoflavones	Johnson & Johnson	Pre-clinical	26
topiramate	Johnson & Johnson	Phase 3	40
Placebo + Zolmitriptan + Zolmitriptan + Zolmitriptan	AstraZeneca	Approved	43
candesartan cilexetil + placebo	AstraZeneca	Phase 2	35
Rizatriptan + Placebo	Merck	Pre-clinical	18
Propranolol or nadolol + Placebo control + Optimal Acute Therapy	Merck	Approved	43
AMG 334	Novartis	Phase 2	35
SOM230 + Placebo	Novartis	Phase 2	27